Thera-SAbDab

TRALOKINUMAB

>   Structural Summary
TherapeuticTralokinumab
TargetIL13
Heavy ChainQVQLVQSGAEVKKPGASVKVSCKASGYTFTNYGLSWVRQAPGQGLEWMGWISANNGDTNYGQEFQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDSSSSWARWFFDLWGRGTLVTVSS
Light ChainSYVLTQPPSVSVAPGKTARITCGGNIIGSKLVHWYQQKPGQAPVLVIYDDGDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDTGSDPVVFGGGTKLTVL
100% seqID Fv Structure5l6y [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (June '19)Phase-III
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2009
INN Year Recommended2010
Companies InvolvedCambridge Antibody Technology, Icahn School of Medicine at Mount Sinai, LEO Pharma, MedImmune
Conditions Approvedna
Conditions ActiveAtopic dermatitis, Alopecia areata
Conditions DiscontinuedAsthma, Chronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Ulcerative colitis
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]